Dietary Iodine Restriction in Preparation for Radioactive Iodine Treatment or Scanning in Well-Differentiated Thyroid Cancer: A Systematic Review

被引:57
|
作者
Sawka, Anna M. [1 ,2 ]
Ibrahim-Zada, Irada
Galacgac, Philip
Tsang, Richard W. [3 ]
Brierley, James D. [3 ]
Ezzat, Shereen [4 ,5 ,6 ]
Goldstein, David P. [7 ,8 ]
机构
[1] Univ Hlth Network, Toronto Gen Hosp, Dept Med, Div Endocrinol, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Dept Med, Div Endocrinol, Toronto, ON, Canada
[3] Univ Hlth Network, Dept Radiat Oncol, Toronto, ON M5G 2C4, Canada
[4] Mt Sinai Hosp, Dept Med, Div Endocrinol, Toronto, ON M5G 1X5, Canada
[5] Freeman Ctr Endocrine Oncol, Toronto, ON, Canada
[6] Ontario Canc Inst, Toronto, ON M4X 1K9, Canada
[7] Univ Hlth Network, Dept Otolaryngol & Head & Neck Surg, Toronto, ON M5G 2C4, Canada
[8] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
OUTPATIENT PREPARATION; CARCINOMA; ABLATION; THERAPY; I-131; LEVOTHYROXINE; HYPONATREMIA; REEVALUATION; ASSOCIATION;
D O I
10.1089/thy.2010.0055
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Dietary iodine is often restricted before radioactive iodine (RAI) scanning or treatment of welldifferentiated thyroid cancer. Our objective was to examine the impact of a low-iodine diet (LID) before RAI treatment or scanning on the following outcomes: (i) the efficacy of thyroid remnant ablation (or residual disease elimination), (ii) urinary iodine measurements, (iii) RAI kinetics, and (iv) long-term thyroid cancer outcomes. Methods: We performed a systematic review of the English literature. We searched four electronic databases and conducted a hand search. Two reviewers independently screened citations and reviewed full-text articles and reached consensus on included articles. Two reviewers independently abstracted data. Results: We reviewed 76 abstracts or citations and 26 full-text articles. Eight studies were included in the review. The most commonly studied diets allowed <= 50 mu g/day of iodine for 1-2 weeks. In one study, 6-month successful remnant ablation rates were higher in patients following an LID than in controls. However, in another study, there was no significant benefit of an LID. LIDs reduce urinary iodine measurements and appear to increase I-131 uptake or lesional radiation compared to regular diets. No studies have examined long-term recurrence or mortality rates. Conclusions: Given that LIDs reduce urinary iodine measurements, increase I-131 uptake, and possibly improve efficacy of I-131 treatment, we currently favor the use of a 1-2-week LID before I-131 therapy or scanning. However, more research is needed to clarify the role of this dietary intervention.
引用
收藏
页码:1129 / 1138
页数:10
相关论文
共 50 条
  • [41] Do Patients with Differentiated Thyroid Cancer Face the Risk of Hyponatremia at the Expense of Preparation for Radioactive Iodine Treatment?
    Ozdemir, Elif
    Polat, Sefika Burcak
    Talay, Nahide Belgit
    EUROPEAN JOURNAL OF THERAPEUTICS, 2020, 26 (03): : 233 - 237
  • [42] Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review)
    Babu, Geethu
    Kainickal, Cessal Thommachan
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (02) : 1 - 7
  • [43] Effect of Psychological Intervention on Differentiated Thyroid Cancer Patients in the Treatment with Radioactive Iodine
    Liu, Yan-Bin
    Zuo, Li-Juan
    Liu, Ya-Chao
    Li, Yan-Ping
    Xin, Yun-Chao
    Zhang, Hong-Yan
    Hou, Li -Yuan
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 731 - 738
  • [44] Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer
    Capdevila, Jaume
    Newbold, Kate
    Licitra, Lisa
    Popovtzer, Axon
    Moreso, Francesc
    Zamorano, Jose
    Kreissl, Michael
    Aller, Javier
    Grande, Enrique
    CANCER TREATMENT REVIEWS, 2018, 69 : 164 - 176
  • [45] Urinary iodine concentration and radioactive iodine therapeutic response in patients with differentiated thyroid cancer
    Jiang, Yuyan
    Jin, Jiahui
    Fan, Jingzheng
    Huang, Chao
    Jia, Qiang
    Tan, Jian
    He, Xianghui
    Zheng, Xiangqian
    Zhao, Yue
    Zhang, Qing
    Meng, Zhaowei
    Wang, Yan
    BIOMARKERS IN MEDICINE, 2021, 15 (11) : 879 - 890
  • [46] A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
    Fleeman, Nigel
    Houten, Rachel
    Chaplin, Marty
    Beale, Sophie
    Boland, Angela
    Dundar, Yenal
    Greenhalgh, Janette
    Duarte, Rui
    Shenoy, Aditya
    BMC CANCER, 2019, 19 (01)
  • [47] A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
    Nigel Fleeman
    Rachel Houten
    Marty Chaplin
    Sophie Beale
    Angela Boland
    Yenal Dundar
    Janette Greenhalgh
    Rui Duarte
    Aditya Shenoy
    BMC Cancer, 19
  • [48] The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma
    Pelikan, DMV
    Lion, HL
    Hermans, J
    Goslings, BM
    CLINICAL ENDOCRINOLOGY, 1997, 47 (06) : 713 - 720
  • [49] Radioactive iodine in differentiated thyroid cancer: a national database perspective
    Orosco, Ryan K.
    Hussain, Timon
    Noel, Julia E.
    Chang, David C.
    Dosiou, Chrysoula
    Mittra, Erik
    Divi, Vasu
    Orloff, Lisa A.
    ENDOCRINE-RELATED CANCER, 2019, 26 (10) : 795 - 802
  • [50] Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer
    Verburg, Frederik A.
    Haenscheid, Heribert
    Luster, Markus
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 31 (03) : 279 - 290